Journal: Oxidative Medicine and Cellular Longevity

Article Title: GLX351322, a Novel NADPH Oxidase 4 Inhibitor, Attenuates TMJ Osteoarthritis by Inhibiting the ROS/MAPK/NF- κ B Signaling Pathways

doi: 10.1155/2023/1952348

Figure Lengend Snippet: Transcriptomic analysis of the TMJ synovium samples from normal and CFA-injected rats. (a) Schematic diagram of the experimental design and procedure for sample preparation for mRNA microarray. (b) Volcano plots of differentially expressed genes (DEGs). (c) Clustered heat map of all targets. (d) Heat map of the inflammation-related genes (fold change ≥ 2.0 and P < 0.05). (e) KEGG pathway enrichment analysis on differentially expressed genes between the control and CFA-injected groups.

Article Snippet: Rat TMJ inflammation was established by intra-articular injection of 5 mg/mL CFA (Chondrex, Redmond, WA, USA) in a 50 μ L volume.

Techniques: Injection, Sample Prep, Microarray

Journal: Oxidative Medicine and Cellular Longevity

Article Title: GLX351322, a Novel NADPH Oxidase 4 Inhibitor, Attenuates TMJ Osteoarthritis by Inhibiting the ROS/MAPK/NF- κ B Signaling Pathways

doi: 10.1155/2023/1952348

Figure Lengend Snippet: General histopathologic changes and radiological evaluation of GLX on CFA-induced TMJ inflammation in rats. (a) Schematic of the in vivo experiments. (b) Histopathologic changes in the rat TMJ after treatment on days 7 and 14 for each group. (c) Micro-CT scanning of rat TMJ after treatment on days 7 and 14 for each group. (d) Quantification of micro-CT scanning of rat TMJ after treatment on days 7 and 14 for each group ( n = 3 independent animals). The data represent the mean ± SD from three independent replicates (one-way ANOVA with Tukey's post hoc tests). ∗ P < 0.05, ∗∗ P < 0.01 compared with the saline group; # P < 0.05, ## P < 0.01 compared with the CFA group.

Article Snippet: Rat TMJ inflammation was established by intra-articular injection of 5 mg/mL CFA (Chondrex, Redmond, WA, USA) in a 50 μ L volume.

Techniques: In Vivo, Micro-CT

Journal: Oxidative Medicine and Cellular Longevity

Article Title: GLX351322, a Novel NADPH Oxidase 4 Inhibitor, Attenuates TMJ Osteoarthritis by Inhibiting the ROS/MAPK/NF- κ B Signaling Pathways

doi: 10.1155/2023/1952348

Figure Lengend Snippet: Histological analysis of the therapeutic effect of GLX on CFA-induced TMJ inflammation in rats. (a) Representative images of H&E, S&F, and immunofluorescence staining of NOX4 on day 7 after treatment from each group. (b) Representative images of H&E, S&F, and immunofluorescence staining of NOX4 on day 14 after treatment from each group. (c) Quantification of the synovitis score ( n = 3 independent animals). (d) Quantification of the OARSI score ( n = 3 independent animals). (e) Quantitative analysis of the relative NOX4 fluorescence (% of saline group) ( n = 3 independent animals). The data represent the mean ± SD from three independent replicates (one-way ANOVA with Tukey's post hoc tests). ∗ P < 0.05, ∗∗ P < 0.01 compared with the saline group; # P < 0.05, ## P < 0.01 compared with the CFA group.

Article Snippet: Rat TMJ inflammation was established by intra-articular injection of 5 mg/mL CFA (Chondrex, Redmond, WA, USA) in a 50 μ L volume.

Techniques: Immunofluorescence, Staining, Fluorescence